These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17172725)

  • 1. Target discovery and validation in pancreatic cancer.
    Beaty RM; Gronborg M; Pollack JR; Maitra A
    Methods Mol Biol; 2007; 360():57-89. PubMed ID: 17172725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic technologies and their application to pancreatic cancer.
    Vimalachandran D; Costello E
    Expert Rev Proteomics; 2004 Dec; 1(4):493-501. PubMed ID: 15966844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis.
    Missiaglia E; Blaveri E; Terris B; Wang YH; Costello E; Neoptolemos JP; Crnogorac-Jurcevic T; Lemoine NR
    Int J Cancer; 2004 Oct; 112(1):100-12. PubMed ID: 15305381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting targets for therapeutic validation through differential protein expression using chromatography-mass spectrometry.
    Patterson S
    Bioinformatics; 2002; 18 Suppl 2():S181. PubMed ID: 12386001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global MS-Based Proteomics Drug Profiling.
    Carvalho AS; Matthiesen R
    Methods Mol Biol; 2016; 1449():469-79. PubMed ID: 27613057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Applications of DNA chip technology and protein mass spectrometry in the studies of reproduction and endocrinology].
    Han CS
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):361-3. PubMed ID: 16831353
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of pancreatic cancer-specific cell-surface markers for development of targeting ligands.
    Morse DL; Hostetter G; Balagurunathan Y; Gillies RJ; Han H
    Methods Mol Biol; 2010; 624():195-210. PubMed ID: 20217597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
    Iacobuzio-Donahue CA; Ashfaq R; Maitra A; Adsay NV; Shen-Ong GL; Berg K; Hollingsworth MA; Cameron JL; Yeo CJ; Kern SE; Goggins M; Hruban RH
    Cancer Res; 2003 Dec; 63(24):8614-22. PubMed ID: 14695172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.
    Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM
    Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesopore-assisted profiling strategies in clinical proteomics for drug/target discovery.
    Savino R; Terracciano R
    Drug Discov Today; 2012 Feb; 17(3-4):143-52. PubMed ID: 22016086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer gene profiling in pancreatic cancer.
    Vilardell F; Iacobuzio-Donahue CA
    Methods Mol Biol; 2010; 576():279-92. PubMed ID: 19882267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.
    Kulasingam V; Diamandis EP
    Nat Clin Pract Oncol; 2008 Oct; 5(10):588-99. PubMed ID: 18695711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape.
    Chen R; Yi EC; Donohoe S; Pan S; Eng J; Cooke K; Crispin DA; Lane Z; Goodlett DR; Bronner MP; Aebersold R; Brentnall TA
    Gastroenterology; 2005 Oct; 129(4):1187-97. PubMed ID: 16230073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics of pancreatic cancer.
    Gräntzdörffer I; Carl-McGrath S; Ebert MP; Röcken C
    Pancreas; 2008 May; 36(4):329-36. PubMed ID: 18437077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of molecular targets of natural products by mass spectrometry.
    Cheng KW; Wong CC; Wang M; He QY; Chen F
    Mass Spectrom Rev; 2010; 29(1):126-55. PubMed ID: 19319922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted discovery tools: proteomics and chromatin immunoprecipitation-on-chip.
    Le Guezennec X; Brinkman AB; Vermeulen M; Denissov SG; Gazziola C; Lohrum ME; Stunnenberg HG
    BJU Int; 2005 Dec; 96 Suppl 2():16-22. PubMed ID: 16359434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma.
    Cui Y; Zhang D; Jia Q; Li T; Zhang W; Han J
    Cancer Invest; 2009 Aug; 27(7):747-55. PubMed ID: 19488907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR.
    Streit S; Michalski CW; Erkan M; Friess H; Kleeff J
    Pancreatology; 2009; 9(5):577-82. PubMed ID: 19657213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel candidate oncogenes in pancreatic carcinoma using high-throughput microarrays.
    Jiang Y; Liu M; Li Z; Jiang Y
    Hepatogastroenterology; 2013; 60(128):1825-32. PubMed ID: 24719914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.